Patients suffering from symptomatic carotid artery stenosis, transient ischemic attacks
(TIAs), amaurosis fugax or stroke receive either Revacept (single dose) plus antiplatelet
monotherapy or monotherapy alone.
Patients receive a single dose of trial medication by intravenous infusion for 20 minutes.
Patients are followed up one and three days after treatment, at 3 months and by a telephone
interview at 12 months.